Medical treatment of pancreatic cancer

References

• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J. Clin.57(1), 43–66 (2007).
   PubMed Web of Science ®Google Scholar
• Büchler MW, Wagner M, Schmied BM, Uhl W, Friess H, Z’Graggen K. Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy. Arch. Surg.138(12), 1310–1314; discussion 1315 (2003).
   PubMedGoogle Scholar
• Löhr M. Is it possible to survive pancreatic cancer? Nat. Clin. Pract. Gastroenterol. Hepatol.3(5), 236–237 (2006).
   PubMedGoogle Scholar
• Greenhalf W. An unfavourable prognosis for pancreatic cancer indicates fields of opportunity. Gut55(11), 1533–1535 (2006).
   PubMed Web of Science ®Google Scholar
• Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat. Rev. Cancer2(12), 897–909 (2002).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, van de Velde H, Karasek P et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol.22(8), 1430–1438 (2004).
   PubMed Web of Science ®Google Scholar
• Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J. Clin. Oncol.19(15), 3447–3455 (2001).
   PubMed Web of Science ®Google Scholar
• Moore MJ, Hamm J, Dancey J et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12–9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol.21(17), 3296–3302 (2003).
   PubMed Web of Science ®Google Scholar
• Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J. Surg.27(3), 324–329 (2003).
   PubMed Web of Science ®Google Scholar
• Cress RD, Yin D, Clarke L, Bold R, Holly EA. Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control17(4), 403–409 (2006).
   PubMed Web of Science ®Google Scholar
• Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br. J. Surg.91(5), 586–594 (2004).
   PubMed Web of Science ®Google Scholar
• Kastl S, Brunner T, Herrmann O et al. Neoadjuvant radio-chemotherapy in advanced primarily non-resectable carcinomas of the pancreas. Eur. J. Surg. Oncol.26(6), 578–582 (2000).
   PubMedGoogle Scholar
• Wolff B. Pancreatic Carcinoma: A Pledge For A More Disciplined Approach. Educational Book. ASCO (2005).
   Google Scholar
• Bockman DE, Buchler M, Beger HG. Interaction of pancreatic ductal carcinoma with nerves leads to nerve damage. Gastroenterology107(1), 219–230 (1994).
   PubMed Web of Science ®Google Scholar
• Willett CG, Del Castillo CF, Shih HA et al. Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer. Ann. Surg.241(2), 295–299 (2005).
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med.350(12), 1200–1210 (2004).
   PubMed Web of Science ®Google Scholar
• Carpelan-Holmstrom M, Nordling S, Pukkala E et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut54(3), 385–387 (2005).
   PubMed Web of Science ®Google Scholar
• Wenz F, Tiefenbacher U, Fuss M, Lohr F. Should patients with locally advanced, non-metastatic carcinoma of the pancreas be irradiated? Pancreatology3(5), 359–365; discussion 365–366 (2003).
   PubMed Web of Science ®Google Scholar
• Regine WF, Winter KW, Abrams R et al. RTOG 9704 a Phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. J. Clin. Oncol.24, S18 (2006).
   Google Scholar
• Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA297(3), 267–277 (2007).
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Stocken DD, Dunn JA et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann. Surg.234(6), 758–768 (2001).
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Dunn JA, Stocken DD et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet358(9293), 1576–1585 (2001).
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Cunningham D, Friess H et al. Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann. Oncol.14(5), 675–692 (2003).
   PubMed Web of Science ®Google Scholar
• Stocken DD, Buchler MW, Dervenis C et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br. J. Cancer92(8), 1372–1381 (2005).
   PubMed Web of Science ®Google Scholar
• Wray CJ, Ahmad SA, Matthews JB, Lowy AM. Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology128(6), 1626–1641 (2005).
   PubMed Web of Science ®Google Scholar
• Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am. J. Surg.185(5), 476–480 (2003).
   PubMed Web of Science ®Google Scholar
• Knaebel HP, Marten A, Schmidt J et al. Phase III trial of postoperative cisplatin, interferon α-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma – CapRI: study protocol [ISRCTN62866759]. BMC Cancer5(1), 37 (2005).
   PubMed Web of Science ®Google Scholar
• Macdonald JS, Jacobson JL, Modiano M et al. A Phase II trial of etoposide, leucovorin, 5-FU, and interferon α 2b (ELFI) + G-CSF for patients with pancreatic adenocarcinoma: a Southwest Oncology Group study (SWOG 9413). Invest. New Drugs18(3), 269–273 (2000).
   PubMed Web of Science ®Google Scholar
• David AK, Vaughn DJ, Holroyde CP, Armstead B, Haller DG. A Phase II trial of 5-fluorouracil, leucovorin, and interferon α 2A (IFN-α 2a) in metastatic pancreatic carcinoma: a Penn Cancer Clinical Trials Group (PCCTG) trial. Am. J. Clin. Oncol.23(1), 37–39 (2000).
   PubMed Web of Science ®Google Scholar
• Wagener DJ, Wils JA, Kok TC, Planting A, Couvreur ML, Baron B. Results of a randomised Phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluorouracil with α-interferon in metastatic pancreatic cancer: an EORTC gastrointestinal tract cancer group trial. Eur. J. Cancer38(5), 648–653 (2002).
   PubMed Web of Science ®Google Scholar
• Jaffee EM, Hruban RH, Biedrzycki B et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a Phase I trial of safety and immune activation. J. Clin. Oncol.19(1), 145–156 (2001).
   PubMed Web of Science ®Google Scholar
• Pascolo S. Messenger RNA-based vaccines. Expert Opin. Biol. Ther.4(8), 1285–1294 (2004).
   PubMed Web of Science ®Google Scholar
• Itoh K, Yamada A. Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci.97(10), 970–976 (2006).
   PubMed Web of Science ®Google Scholar
• Nakao A, Fujii T, Sugimoto H et al. Oncological problems in pancreatic cancer surgery. World J. Gastroenterol.12(28), 4466–4472 (2006).
   PubMed Web of Science ®Google Scholar
• Heinemann V, Quietzsch D, Gieseler F et al. Randomized Phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J. Clin. Oncol.24(24), 3946–3952 (2006).
   PubMed Web of Science ®Google Scholar
• Louvet C, Labianca R, Hammel P et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD Phase III trial. J. Clin. Oncol.23(15), 3509–3516 (2005).
   PubMed Web of Science ®Google Scholar
• Willett CG, Czito BG, Bendell JC, Ryan DP. Locally advanced pancreatic cancer. J. Clin. Oncol.23(20), 4538–4544 (2005).
   PubMed Web of Science ®Google Scholar
• Brunner TB, Grabenbauer GG, Kastl S et al. Preoperative chemoradiation in locally advanced pancreatic carcinoma: a Phase II study. Onkologie23(5), 436–442 (2000).
   PubMedGoogle Scholar
• Chauffert B, Mornex F, Bonnetain F et al. Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: a FFCD-SFRO study. J. Clin. Oncol.24, 4008 (2006).
   Google Scholar
• Martin NE, Brunner TB, Kiel KD et al. A Phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer. Clin. Cancer Res.10(16), 5447–5454 (2004).
   PubMed Web of Science ®Google Scholar
• Krishnan S, Rana V, Janjan NA et al. Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer107(11), 2589–2596 (2006).
   PubMed Web of Science ®Google Scholar
• Atkins JH, Gershell LJ. Selective anticancer drugs. Nat. Rev. Drug Discov.1(7), 491–492 (2002).
   PubMed Web of Science ®Google Scholar
• Glimelius B, Hoffman K, Sjoden PO et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann. Oncol.7(6), 593–600 (1996).
   PubMed Web of Science ®Google Scholar
• Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R. An investigational new drug treatment program for patients with gemcitabine. Cancer85, 1261–1268 (1999).
   PubMed Web of Science ®Google Scholar
• Burris HA, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J. Clin. Oncol.15, 2403–2413 (1997).
   PubMed Web of Science ®Google Scholar
• Tempero M, Plunkett W, Ruiz Van Haperen V et al. Randomized Phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J. Clin. Oncol.21(18), 3402–3408 (2003).
   PubMed Web of Science ®Google Scholar
• Poplin E, Levy DE, Berlin J et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). J. Clin. Oncol.24, S18 (2006).
   Google Scholar
• Rocha Lima CM, Green MR, Rotche R et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J. Clin. Oncol.22(18), 3776–3783 (2004).
   PubMed Web of Science ®Google Scholar
• Taieb J, Lecomte T, Aparicio T et al. FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter Phase II study. Ann. Oncol.18(3), 498–503 (2006).
   PubMed Web of Science ®Google Scholar
• Lutz MP, Van Cutsem E, Wagener T et al. Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized Phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group. J. Clin. Oncol.23(36), 9250–9256 (2005).
   PubMed Web of Science ®Google Scholar
• Heinemann V, Hinke A, Böck S, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from combination chemotherapy applied in advanced pancreatic cancer. Ann. Oncol.17(Suppl. 9), O1073 (2006).
   Google Scholar
• Milella M, Bria E, Carlini P. Does a second drug added to gemcitabine improves outcome over gemcitabine in advanced pancreatic cancert? Ann. Oncol.17(Suppl. 9), O1074 (2006).
   Google Scholar
• Cunningham D, Chau I, Stocken D et al. Phase III randomised comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Eur. J. Cancer (Suppl. 3), 4 (2005).
   Google Scholar
• Yip D, Karapetis C, Strickland A, Steer CB, Goldstein D. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst. Rev.3, CD002093 (2006).
   Google Scholar
• Bernhardt SL, Gjertsen MK, Trachsel S et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating Phase I/II study. Br. J. Cancer95(11), 1474–1482 (2006).
   PubMed Web of Science ®Google Scholar
• Koki AT, Leahy KM, Masferrer JL. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin. Investig. Drugs8(10), 1623–1638 (1999).
   PubMedGoogle Scholar
• Ferrari V, Valcamonico F, Amoroso V et al. Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a Phase II trial. Cancer Chemother. Pharmacol.57(2), 185–190 (2006).
   PubMed Web of Science ®Google Scholar
• El-Rayes BF, Zalupski MM, Shields AF et al. A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Invest. New Drugs23(6), 583–590 (2005).
   PubMed Web of Science ®Google Scholar
• Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N. Engl. J. Med.343(25), 1846–1850 (2000).
   PubMed Web of Science ®Google Scholar
• Trousseau A. Phlegmasia alba dolens. Clinique Médicale Hotel-Dieu Paris3, 654–659 (1865).
   Google Scholar
• Haas SL, Jesnowski R, Steiner M et al. Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation. World J. Gastroenterol.12(30), 4843–4849 (2006).
   PubMed Web of Science ®Google Scholar
• Maurer LH, Herndon JE II, Hollis DR et al. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. J. Clin. Oncol.15(11), 3378–3387 (1997).
   PubMed Web of Science ®Google Scholar
• Nakchbandi W, Muller H, Singer MV, Lohr M, Nakchbandi IA. Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma. Scand. J. Gastroenterol.41(9), 1095–1104 (2006).
   PubMed Web of Science ®Google Scholar
• Oettle H, Pelzer H, Stieler J et al. Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy ofgemcitabine-refractory advanced pancreatic cancer (CONKO 003). J. Clin. Oncol.23(Suppl.), S16 (2005).
   Google Scholar
• Wiedmann MW, Caca K. Molecularly targeted therapy for gastrointestinal cancer. Curr. Cancer Drug Targets5(3), 171–193 (2005).
   PubMed Web of Science ®Google Scholar
• Xiong HQ, Rosenberg A, LoBuglio A et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter Phase II Trial. J. Clin. Oncol.22(13), 2610–2616 (2004).
   PubMed Web of Science ®Google Scholar
• Safran H, Ramanathan RK, Schwartz J et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Proc. Am. Soc. Clin. Oncol.20, A517 (2001).
   Google Scholar
• Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A Phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. J. Clin. Oncol.23, S16 (2005).
   Google Scholar
• Chen J, Rocken C, Nitsche B et al. The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression. Cancer Lett.233(2), 328–337 (2006).
   PubMed Web of Science ®Google Scholar
• Oettle H, Richards D, Ramanathan RK et al. A Phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann. Oncol.16(10), 1639–1645 (2005).
   PubMed Web of Science ®Google Scholar
• Kralidis E, Aebi S, Friess H, Buchler MW, Borner MM. Activity of raltitrexed and gemcitabine in advanced pancreatic cancer. Ann. Oncol.14(4), 574–579 (2003).
   PubMed Web of Science ®Google Scholar
• Kindler HL, Bylow KA, Hochster HS et al. A randomized Phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis. J. Clin. Oncol.24, S18 (2006).
   Google Scholar
• Cohen SJ, Ho L, Ranganathan S et al. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J. Clin. Oncol.21(7), 1301–1306 (2003).
   PubMed Web of Science ®Google Scholar
• Frantz S. Drug discovery: playing dirty. Nature437(7061), 942–943 (2005).
   PubMed Web of Science ®Google Scholar
• Overall CM, Kleifeld O. Tumour microenvironment – opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer6(3), 227–2239 (2006).
   PubMed Web of Science ®Google Scholar
• Korc M. Pathways for aberrant angiogenesis in pancreatic cancer. Mol. Cancer2, 8 (2003).
   PubMedGoogle Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350(23), 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Kindler HL, Friberg G, Singh DA et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol.23(31), 8033–8040 (2005).
   PubMed Web of Science ®Google Scholar
• Kindler HL, Niedzwiecki D, Hollis DR et al. A double-blind, placebo-controlled, randomized Phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. J. Clin. Oncol.26, A108 (2007).
   Google Scholar
• Schuch G. EndoTAG-1. MediGene. Curr. Opin. Investig. Drugs6(12), 1259–1265 (2005).
   PubMedGoogle Scholar
• Jimeno A, Hidalgo M. Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol. Cancer Ther.5(4), 787–796 (2006).
   PubMed Web of Science ®Google Scholar
• Hochster HS, Haller DG, de Gramont A et al. Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Cancer107(4), 676–685 (2006).
   PubMed Web of Science ®Google Scholar
• Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR. American Society of Clinical Oncology technology assessment: chemotherapy sensitivity and resistance assays. J. Clin. Oncol.22(17), 3631–3638 (2004).
   PubMed Web of Science ®Google Scholar
• Samson DJ, Seidenfeld J, Ziegler K, Aronson N. Chemotherapy sensitivity and resistance assays: a systematic review. J. Clin. Oncol.22(17), 3618–3630 (2004).
   PubMed Web of Science ®Google Scholar
• Brandt R, Grutzmann R, Bauer A et al. DNA microarray analysis of pancreatic malignancies. Pancreatology4(6), 587–597 (2004).
   PubMed Web of Science ®Google Scholar
• Chen R, Pan S, Brentnall TA, Aebersold R. Proteomic profiling of pancreatic cancer for biomarker discovery. Mol. Cell Proteomics4(4), 523–533 (2005).
   PubMed Web of Science ®Google Scholar
• Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell53, 549–554 (1988).
   PubMed Web of Science ®Google Scholar
• Löhr M, Müller P, Schmidt C et al. Immortalized bovine pancreatic duct cells become tumorigenic after transfection with mutant k-ras. Virch. Arch.438, 581–590 (2001).
   PubMed Web of Science ®Google Scholar
• Hingorani SR, Petricoin EF, Maitra A et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell4(6), 437–450 (2003).
   PubMed Web of Science ®Google Scholar
• Kim J, Reber HA, Dry SM et al. Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins. Gut55(11), 1598–1605 (2006).
   PubMed Web of Science ®Google Scholar
• Raper SE, Chirmule N, Lee FS et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab.80(1–2), 148–158 (2003).
   PubMed Web of Science ®Google Scholar
• Löhr M. Gene therapy approaches to gastrointestinal tumors. Z. Gastroenterol.44(4), 333–340 (2006).
   PubMed Web of Science ®Google Scholar
• Löhr M, Hoffmeyer A, Kroger J et al. Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet357(9268), 1591–1592 (2001).
   PubMed Web of Science ®Google Scholar
• Löhr M, Hoffmeyer A, Kröger JC et al. Safety, feasibility and clinical benefit of localized chemotherapy using microencapsulated cells for inoperable pancreatic carcinoma: a Phase I/II trial. Cancer Therapy1, 121–131 (2003).
   Google Scholar
• Kasuya H, Takeda S, Nomoto S, Nakao A. The potential of oncolytic virus therapy for pancreatic cancer. Cancer Gene Ther.12(9), 725–736 (2005).
   PubMed Web of Science ®Google Scholar
• Ruan DT, Warren RS. Liver-directed therapies in colorectal cancer. Semin. Oncol.32(1), 85–94 (2005).
   PubMed Web of Science ®Google Scholar
• Mulvihill S, Warren R, Venook A et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a Phase I trial. Gene Ther.8(4), 308–315 (2001).
   PubMed Web of Science ®Google Scholar
• Hecht JR, Bedford R, Abbruzzese JL et al. A Phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin. Cancer Res.9(2), 555–561 (2003).
   PubMed Web of Science ®Google Scholar
• Reid T, Galanis E, Abbruzzese J et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a Phase I trial. Gene Ther.8(21), 1618–1626 (2001).
   PubMed Web of Science ®Google Scholar
• Bitzer M, Lauer UM. Oncolytic viruses for genetic therapy of gastrointestinal tumors. Z. Gastroenterol.41(7), 667–674 (2003).
   PubMed Web of Science ®Google Scholar
• Reid TR, Freeman S, Post L, McCormick F, Sze DY. Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther. (2005).
   PubMedGoogle Scholar
• Holm PS, Lage H, Bergmann S et al. Multidrug-resistant cancer cells facilitate E1-independent adenoviral replication: impact for cancer gene therapy. Cancer Res.64(1), 322–328 (2004).
   PubMed Web of Science ®Google Scholar
• Chen R, Yi EC, Donohoe S et al. Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunologic escape. Gastroenterology29(4), 1187–1197 (2005).
   Google Scholar
• Singh AP, Chaturvedi P, Batra SK. Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy. Cancer Res.67(2), 433–436 (2007).
   Google Scholar
• Witkop B. Paul Ehrlich and his magic bullets – revisited. Proc. Am. Philos. Soc.143(4), 540–557 (1999).
   PubMed Web of Science ®Google Scholar
• Erickson RP. From ‘magic bullet’ to ‘specially engineered shotgun loads’: the new genetics and the need for individualized pharmacotherapy. Bioessays20(8), 683–685 (1998).
   PubMed Web of Science ®Google Scholar
• Gjertsen MK, Buanes T, Rosseland AR et al. Intradermal ras peptide vaccination with granulocyte–macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int. J. Cancer92(3), 441–450 (2001).
   PubMed Web of Science ®Google Scholar
• Brett BT, Smith SC, Bouvier CV et al. Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J. Clin. Oncol.20(20), 4225–4231 (2002).
   PubMed Web of Science ®Google Scholar
• Chau I, Cunningham D, Russell C et al. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br. J. Cancer94(8), 1107–1115 (2006).
   PubMed Web of Science ®Google Scholar
• Hehlgans S, Haase M, Cordes N. Signalling via integrins: implications for cell survival and anticancer strategies. Biochim. Biophys. Acta1775(1), 163–180 (2007).
   PubMed Web of Science ®Google Scholar
• Miyamoto H, Murakami T, Tsuchida K, Sugino H, Miyake H, Tashiro S. Tumor–stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas28(1), 38–44 (2004).
   PubMed Web of Science ®Google Scholar
• Garber K. Personal mouse colonies give hope for pancreatic cancer patients. J. Natl Cancer Inst.99(2), 105–107 (2007).
   PubMedGoogle Scholar
• Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Del Tacca M, Danesi R. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol. Cancer Ther.5(6), 1387–1395 (2006).
   PubMed Web of Science ®Google Scholar
• Yang GY, Wagner TD, Fuss M, Thomas CR Jr. Multimodality approaches for pancreatic cancer. CA Cancer J. Clin.55(6), 352–367 (2005).
   PubMed Web of Science ®Google Scholar
• Riess H, Helm A, Niedergethmann M et al. A randomised, prospective, multicenter, Phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer. 2005 ASCO Ann. Meeting Proc. J. Clin. Oncol.23(S16), 4009 (2005).
   Google Scholar
• Heinemann V, Hoehler T, Seipelt G et al. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (GemOx): a randomized Phase II trial in advanced pancreatic cancer. 2005 ASCO Ann. Meeting Proc. J. Clin. Oncol.23(S16), 4030 (2005).
   Google Scholar
• Herrmann R, Bodoky G, Ruhstaller T et al. Gemcitabine (G) plus capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized Phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). 2005 ASCO Ann. Meeting Proc. J. Clin. Oncol.23(S16), 4010 (2005).
   Google Scholar
• Stathopoulos GP, Syrigos K, Aravantinos G et al. A multicenter Phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br. J. Cancer95(5), 587–592 (2006).
   PubMed Web of Science ®Google Scholar
• Richards DA, Kindler HL, Oettle H et al. A randomized Phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer. 2004 ASCO Ann. Meeting Proc. J. Clin. Oncol.22(S14), 4007 (2004).
   Google Scholar
• Kindler HL, Friberg G, Stadler WM et al. Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): updated results of a multi-center Phase II trial. J. Clin. Oncol.22, S14 (2004).
   Google Scholar
• Safran H, Iannitti D, Miner T et al. GW572016, gemcitabine and GW572016, gemcitabine, oxaliplatin, a two-stage, Phase I study for advanced pancreaticobiliary cancer. 2006 ASCO Ann. Meeting Proc. J. Clin. Oncol.24(S18), 4002 (2006).
   Google Scholar
• Sobol RE, Shawler DL, Carson C et al. Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: a Phase I study. Clin. Cancer Res.5(9), 2359–2365 (1999).
   PubMed Web of Science ®Google Scholar
• Gordon EM, Cornelio GH, Lorenzo CC III et al. First clinical experience using a ‘pathotropic’ injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer. Int. J. Oncol.24(1), 177–185 (2004).
   PubMed Web of Science ®Google Scholar